Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer

BACKGROUND: Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant breast cance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
Hauptverfasser: Liu, Bowen, Wang, Tianjiao, Wang, Huawei, Zhang, Lu, Xu, Feifei, Fang, Runping, Li, Leilei, Cai, Xiaoli, Wu, Yue, Zhang, Weiying, Ye, Lihong
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2018
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824486/
https://ncbi.nlm.nih.gov/pubmed/29471853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0577-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge